Abstract

To obtain therapeutically effective new antibiotics, we first searched for bacterial culture supernatants with antimicrobial activity in vitro and then performed a secondary screening using the silkworm infection model. Through further purification of the in vivo activity, we obtained a compound with a previously uncharacterized structure and named it 'lysocin E'. Lysocin E interacted with menaquinone in the bacterial membrane to achieve its potent bactericidal activity, a mode of action distinct from that of any other known antibiotic, indicating that lysocin E comprises a new class of antibiotic. This is to our knowledge the first report of a direct interaction between a small chemical compound and menaquinone that leads to bacterial killing. Furthermore, lysocin E decreased the mortality of infected mice. To our knowledge, lysocin E is the first compound identified and purified by quantitative measurement of therapeutic effects in an invertebrate infection model that exhibits robust in vivo effects in mammals.

  • Compound C75H116N20O20

    Lysocin E

  • Compound C75H118N20O21

    Linearized lysocin E

  • Compound C75H118N20O20 18O

    18O-Labeled linearized lysocin E

  • Compound C75H120N20O20

    Reduced lysocin E

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , & Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38, 1279–1286 (2004).

  2. 2.

    , , & Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29–40 (2007).

  3. 3.

    , , & Silkworm larvae as an animal model of bacterial infection pathogenic to humans. Microb. Pathog. 32, 183–190 (2002).

  4. 4.

    et al. Quantitative evaluation of the therapeutic effects of antibiotics using silkworms infected with human pathogenic microorganisms. Antimicrob. Agents Chemother. 48, 774–779 (2004).

  5. 5.

    , , , & Silkworm as a model animal to evaluate drug candidate toxicity and metabolism. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 149, 334–339 (2009).

  6. 6.

    et al. Nosokomycins, new antibiotics discovered in an in vivo-mimic infection model using silkworm larvae. I: Fermentation, isolation and biological properties. J. Antibiot. (Tokyo) 63, 151–155 (2010).

  7. 7.

    , & Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 2538–2544 (2003).

  8. 8.

    , , & Molecular mechanism of membrane permeabilization by the peptide antibiotic surfactin. Biochim. Biophys. Acta 1611, 91–97 (2003).

  9. 9.

    et al. Mechanism of membrane damage induced by the amphipathic peptides gramicidin S and melittin. Biochim. Biophys. Acta 983, 135–141 (1989).

  10. 10.

    & Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth. J. Bacteriol. 140, 424–435 (1979).

  11. 11.

    , , & Streptococcus faecium mutants that are temperature sensitive for cell growth and show alterations in penicillin-binding proteins. J. Bacteriol. 169, 2432–2439 (1987).

  12. 12.

    , & RNA polymerase mutants of Escherichia coli. III. A temperature-sensitive rifampicin-resistant mutant. Mol. Gen. Genet. 143, 233–241 (1976).

  13. 13.

    et al. Genetic identification of two distinct DNA polymerases, DnaE and PolC, that are essential for chromosomal DNA replication in Staphylococcus aureus. Mol. Genet. Genomics 266, 564–571 (2001).

  14. 14.

    , , , & Isolation and characterization of temperature-sensitive mutants of the Staphylococcus aureus dnaC gene. FEMS Microbiol. Lett. 210, 157–164 (2002).

  15. 15.

    et al. Isolation and mutation site determination of the temperature-sensitive murB mutants of Staphylococcus aureus. FEMS Microbiol. Lett. 222, 107–113 (2003).

  16. 16.

    et al. Identification of temperature-sensitive dnaD mutants of Staphylococcus aureus that are defective in chromosomal DNA replication. Mol. Genet. Genomics 271, 447–457 (2004).

  17. 17.

    , , , & Isolation of a temperature-sensitive dnaA mutant of Staphylococcus aureus. FEMS Microbiol. Lett. 254, 19–26 (2006).

  18. 18.

    et al. Isolation of temperature-sensitive mutations in murC of Staphylococcus aureus. FEMS Microbiol. Lett. 274, 204–209 (2007).

  19. 19.

    & Biosynthesis of vitamin K (menaquinone) in bacteria. Microbiol. Rev. 46, 241–280 (1982).

  20. 20.

    et al. Menaquinone biosynthesis potentiates haem toxicity in Staphylococcus aureus. Mol. Microbiol. 86, 1376–1392 (2012).

  21. 21.

    et al. Staphylococcus aureus small colony variants are resistant to the antimicrobial peptide lactoferricin B. J. Antimicrob. Chemother. 56, 1126–1129 (2005).

  22. 22.

    et al. Evaluation of target specificity of antibacterial agents using Staphylococcus aureus ddlA mutants and d-cycloserine in a silkworm infection model. Antimicrob. Agents Chemother. 53, 4025–4027 (2009).

  23. 23.

    et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat. Rev. Microbiol. 4, 295–305 (2006).

  24. 24.

    & Humic acid-vitamin agar, a new medium for the selective isolation of soil actinomycetes. J. Ferment. Technol. 65, 501–509 (1987).

  25. 25.

    & Phylogenetic analysis of the genus Actinoplanes and transfer of Actinoplanes minutisporangius Ruan et al. 1986 and 'Actinoplanes aurantiacus' to Cryptosporangium minutisporangium comb. nov. and Cryptosporangium aurantiacum sp. nov. Int. J. Syst. Evol. Microbiol. 51, 2119–2125 (2001).

  26. 26.

    , , & MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24, 1596–1599 (2007).

  27. 27.

    , , , & The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25, 4876–4882 (1997).

  28. 28.

    & in Mammalian Protein Metabolism (Academic Press, New York, 1969).

  29. 29.

    & The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4, 406–425 (1987).

  30. 30.

    Confidence limits on phylogenies: an approach using the bootstrap. Evolution 39, 783–791 (1985).

  31. 31.

    et al. Simultaneous determination of hydrophilic amino acid enantiomers in mammalian tissues and physiological fluids applying a fully automated micro-two-dimensional high-performance liquid chromatographic concept. J. Chromatogr. A 1217, 1056–1062 (2010).

  32. 32.

    , , & Enantioselective two-dimensional high-performance liquid chromatographic determination of amino acids; analysis and physiological significance of d-amino acids in mammals. Chromatography 35, 49–57 (2014).

  33. 33.

    Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard—Eighth Edition (CLSI document M07–A8) (Clinical and Laboratory Standards Institute, Wayne, PA, 2009).

  34. 34.

    Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard (CLSI document M27-A) (Clinical and Laboratory Standards Institute, Wayne, PA, 1997).

  35. 35.

    National Committee for Clinical Laboratory Standards. Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline (NCCLS document M26-A) (National Committee for Clinical Laboratory Standards, Wayne, PA, 1999).

  36. 36.

    , & Katanosin B and plusbacin A3, inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45, 1823–1827 (2001).

  37. 37.

    et al. Identification of novel deoxyribofuranosyl indole antimicrobial agents. J. Antibiot. (Tokyo) 65, 53–57 (2012).

  38. 38.

    & Assessment of the Membrane Potential, Intracellular pH and Respiration of Bacteria Employing Fluorescence Techniques (Kluwer Academic Publishers, Netherlands, 2004).

  39. 39.

    , , & Continuous real-time monitoring of cationic porphyrin-induced photodynamic inactivation of bacterial membrane functions using electrochemical sensors. Photochem. Photobiol. Sci. 10, 1181–1188 (2011).

  40. 40.

    et al. Identification and characterization of amino acid residues essential for the active site of UDP-N-acetylenolpyruvylglucosamine reductase (MurB) from Staphylococcus aureus. J. Biol. Chem. 281, 1714–1724 (2006).

  41. 41.

    et al. Silkworm pathogenic bacteria infection model for identification of novel virulence genes. Mol. Microbiol. 56, 934–944 (2005).

  42. 42.

    , & Novel streptococcal-integration shuttle vectors for gene cloning and inactivation. Gene 120, 105–110 (1992).

  43. 43.

    , & Interaction of cationic antimicrobial peptides with model membranes. J. Biol. Chem. 276, 35714–35722 (2001).

  44. 44.

    et al. Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob. Agents Chemother. 49, 3302–3310 (2005).

Download references

Acknowledgements

This study was supported by a grant from Genome Pharmaceuticals Institute Co., Ltd. for K.S., the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO) for K.S., a Grant-in-Aid for Young Scientists (A; 24689008) for H.H., a Grant-in-Aid for Scientific Research (25460036) for T. Katsu from Japan Society for the Promotion of Science (JSPS), a Grant-in-Aid for Scientific Research on Innovative Areas–Chemical Biology of Natural Products to K.S. (24102510) and to H.H. (26102714) from MEXT, and it was supported in part by a Grant-in-Aid for JSPS Fellows (24-11042) for K.I. from JSPS and the Japan Science and Technology Agency (JST) A-STEP (High-Risk Challenging Type). We thank A. Noguchi, F. Aihara and S. Nishida (Genome Pharmaceutical Institute, Co., Ltd.) for screening and production of lysocin E. We thank K. Sakamoto (Hirosaki University) for advice regarding the menaquinone analysis. We thank M. Hyodo (Okayama University), K. Kyogoku (University of Tokyo) and Y. Matsuzawa (Genome Pharmaceutical Institute, Co., Ltd.) for technical assistance. We thank Shiseido Co. Ltd. for their technical support in 2D-HPLC analyses.

Author information

Author notes

    • Makoto Urai

    Present address: Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan.

    • Hiroshi Hamamoto
    • , Makoto Urai
    •  & Kenichi Ishii

    These authors contributed equally to this work.

Affiliations

  1. Laboratory of Microbiology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.

    • Hiroshi Hamamoto
    • , Makoto Urai
    • , Kenichi Ishii
    • , Jyunichiro Yasukawa
    • , Atmika Paudel
    • , Jie Su
    • , Tatsuo Adachi
    •  & Kazuhisa Sekimizu
  2. Laboratory of Synthetic Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.

    • Motoki Murai
    • , Takuya Kaji
    • , Takefumi Kuranaga
    •  & Masayuki Inoue
  3. Department of Drug Discovery and Evolution, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

    • Kenji Hamase
  4. Department of Pharmacy, Graduate School of Pharmacy, Yasuda Women's University, Hiroshima, Japan.

    • Takashi Katsu
  5. Department of Microbial Chemistry, Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.

    • Ryuji Uchida
    •  & Hiroshi Tomoda
  6. Department of Physiological Chemistry and Metabolism, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

    • Maki Yamada
    •  & Hiroki Kurihara
  7. Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Tokyo, Japan.

    • Maki Yamada
    •  & Hiroki Kurihara
  8. MASIS Inc., Aomori, Japan.

    • Manabu Souma

Authors

  1. Search for Hiroshi Hamamoto in:

  2. Search for Makoto Urai in:

  3. Search for Kenichi Ishii in:

  4. Search for Jyunichiro Yasukawa in:

  5. Search for Atmika Paudel in:

  6. Search for Motoki Murai in:

  7. Search for Takuya Kaji in:

  8. Search for Takefumi Kuranaga in:

  9. Search for Kenji Hamase in:

  10. Search for Takashi Katsu in:

  11. Search for Jie Su in:

  12. Search for Tatsuo Adachi in:

  13. Search for Ryuji Uchida in:

  14. Search for Hiroshi Tomoda in:

  15. Search for Maki Yamada in:

  16. Search for Manabu Souma in:

  17. Search for Hiroki Kurihara in:

  18. Search for Masayuki Inoue in:

  19. Search for Kazuhisa Sekimizu in:

Contributions

H.H. performed screening and purification, chemical structure analysis, mechanism analysis, acute toxicity analysis and manuscript drafting. M.U. performed chemical structure analysis and mechanism analysis, and drafted the supplementary results. K.I. performed bacterial genetic analysis, mechanism analysis and manuscript drafting. J.Y. performed bacterial genetic analysis and mechanism analysis. A.P. performed screening and purification and mechanism analysis. M.M., T. Kaji, T. Kuranaga and M.I. critically discussed and confirmed the lysocin E chemical structure. K.H. performed chemical structure analysis. T. Katsu and J.S. performed mechanism analysis. T.A. performed bacterial genetic analysis. R.U. performed analysis of nosokomycin A. H.T. performed analysis of nosocomycin A and critically revised the article for important intellectual content. M.Y. and H.K. performed acute toxicity analysis. M.S. performed chemical structure analysis. K.S. critically revised the article for important intellectual content and final approval of the article.

Competing interests

K.S. is a consultant for Genome Pharmaceutical Institute Co., Ltd.

Corresponding author

Correspondence to Kazuhisa Sekimizu.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Results, Supplementary Note, Supplementary Figures 1–22 and Supplementary Tables 1–9.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nchembio.1710

Further reading